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FIGURE 1 Association Between Log-Transformed Risk of All Bleeding and ST With
Noncardiovascular and Cardiovascular Mortality, Respectively
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The size of each circle represents the precision of each estimate (the inverse variance of
the log relative risk in the trial), and the line is the best ﬁt for the metaregression model.We read with interest the meta-analyses of Giustino
et al. (1) and Palmerini et al. (2) recently published in
the Journal. These studies add meaningfully to the
ongoing debate on dual antiplatelet therapy (DAPT)
duration, but their conclusions on mortality are
conﬂicting, with Giustino et al. (1) concluding that
prolonging DAPT increases all-cause mortality and
Palmerini et al. (2) demonstrating no signiﬁcant effect
on this endpoint. Indeed, addressing the net beneﬁt of
extended DAPT requires preliminary clariﬁcation of
the relative weights of stent thrombosis (ST) and
bleeding on mortality, an issue that has not been
explored by any trial or meta-analysis of DAPT dura-
tion. We hypothesized that in the contemporary era of
drug-eluting stents, ST and bleeding have a different
impact on mortality. To explore this hypothesis, we
performed a meta-regression of the effects sizes of ST
and bleeding on mortality in trials of DAPT duration,
including the recently presented I-LOVE-IT (EvaluateSafety and Effectiveness of the Tivoli DES and the
Firebird DES for Treatment of Coronary) 2 randomized
substudy (China Interventional Therapeutics, March
19, 2015, Beijing, China). Trials were excluded if
the outcomes of interest were not available. Risk ratios
for treatment effects in individual trials were
log-transformed before being used as independent
variables in linear meta-regression analyses. Statisti-
cal analyses were performed using the open-source
R Software (R Foundation for Statistical Computing,
Vienna, Austria). We found a signiﬁcant association
between all bleeding and noncardiovascular mortality
across individual studies (8 trials; intercept value [IV]:
-0.15; slope estimate [SE]: 0.61; p ¼ 0.01) (Figure 1, top
graph), while there was no evidence of a signiﬁcant
correlation of all bleeding with both cardiovascular (8
trials; IV: -0.46; SE: -0.17; p ¼ 0.69) and all-cause
mortality (10 trials; IV: -0.33; SE: 0.75; p ¼ 0.18). On
the other hand, no signiﬁcant associations were found
between ST and both cardiovascular (9 trials; IV: 0.75;
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1640SE: 0.71; p¼0.31) (Figure 1, bottom graph) and all-cause
mortality (11 trials; IV: 0.52; SE: -0.86; p ¼ 0.42).
The observed signiﬁcant link between bleeding and
noncardiovascular mortality is consistent with a pat-
tern already noted in the DAPT trial, where bleeding-
related, trauma-related, and cancer-related causes
primarily contributed to the observed higher risk of
all-cause mortality with prolonged DAPT (3). Con-
versely, we did not ﬁnd the risk of ST across DAPT trials
to be signiﬁcantly associated with cardiovascular mor-
tality. Indeed, it has been suggested that the association
between ST and mortality depends on timing, with late
ST less likely to present with fatal outcomes (4).
The observational nature of meta-regressions car-
ries major unavoidable limitations, including the risk
of incorrect conclusions caused by ecological fallacy
(i.e., when inferences about individuals are made on
the basis of aggregate statistics). To account for
2 other potential limitations of this regression
approach: 1) effect size in the analysis is treated as a
ﬁxed regressor ignoring the degree of variance of the
variable entered in the model; and 2) the unknown
covariance among effect sizes determined by the
presence of a within-study correlation among dif-
ferent reported outcomes—we also used a multivar-
iate meta-analytic approach (5) to explore the
consistency of our ﬁndings and conﬁrmed a
moderate-to-strong relationship between the log
odds ratios for all bleeding and noncardiovascular
mortality (rho coefﬁcient ¼ 0.52), whereas only a
weak association was demonstrated between the log
odds ratio for ST and cardiovascular mortality (rho
coefﬁcient ¼ 0.24).
In conclusion, in drug-eluting stent trials of DAPT
duration, bleeding seems to be signiﬁcantly associated
with noncardiovascular mortality, whereas ST doesnot seem to be signiﬁcantly associated with cardio-
vascular mortality. Therefore, DAPT prolongation over
current recommendations should only be undertaken
after careful consideration of the beneﬁt-risk balance.*Davide Capodanno, MD, PhD
Giuseppe Gargiulo, MD
Sergio Buccheri, MD
Daniele Giacoppo, MD
Piera Capranzano, MD
Corrado Tamburino, MD, PhD
*Division of Cardiology
Ferrarotto Hospital
University of Catania, Italy
Citelli 1
Catania 95124
Italy
E-mail: dcapodanno@gmail.com
http://dx.doi.org/10.1016/j.jacc.2015.05.085
Please note: The authors have reported that they have no relationships relevant
to the contents of this paper to disclose. Sanjay Kaul, MD, served as Guest Editor
for this paper.
R EF E RENCE S
1. Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy
after drug-eluting stent implantation: a systematic review and meta-analysis
of randomized controlled trials. J Am Coll Cardiol 2015;65:1298–310.
2. Palmerini T, Sangiorgi D, Valgimigli M, et al. Short- versus long-term dual
antiplatelet therapy after drug-eluting stent implantation. An individual pa-
tient data pairwise and network meta-analysis. J Am Coll Cardiol 2015;65:
1092–102.
3. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual
antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:
2155–66.
4. Secemsky EA, Matteau A, Yeh RW, et al. Comparison of short- and long-
term cardiac mortality in early versus late stent thrombosis (from Pooled
PROTECT Trials). Am J Cardiol 2015;115:1678–84.
5. Wei Y, Higgins JP. Estimating within-study covariances in multivariate
meta-analysis with multiple outcomes. Stat Med 2013;32:1191–205.
